Coexpression of Multiple ABC‐Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia. Issue 2 (29th October 2015)

• Record Type: Journal Article
• Authors: Bartholomae, Stephan; Gruhn, Bernd; Debatin, Klaus‐Michael; Zimmermann, Martin; Creutzig, Ursula; Reinhardt, Dirk; Steinbach, Daniel
• Is Part Of: Pediatric blood & cancer. Volume 63:Issue 2(2016)
• Page Start: 242
• Page End: 247
• Publication Date: 2015-10-29
• Subjects: breast cancer resistance protein -- multidrug resistance‐associated protein -- multidrug resistance gene -- pediatric AML -- risk group; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25785
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract : Background: To analyze whether expression of ABC‐transporters is associated with remission rate and long‐term outcome in a prospective clinical trial of childhood acute myeloid leukemia (AML). Procedure: The expression of four ABC‐transporter genes ( ABCA3 encoding drug transporter ABCA3, ABCB1 encoding multidrug resistance protein 1, ABCC3 encoding multidrug resistance‐associated protein 3, and ABCG2 encoding breast cancer resistance protein) was measured by TaqMan real time polymerase chain reaction in pretreatment samples from 112 children with AML. Patients were treated according to multicenter study AML‐Berlin, Frankfurt, Munich (BFM) 2004. Results: ABCC3 ( P = 0.009) and ABCG2 ( P = 0.03) were associated with a lower chance to achieve remission after the first course of chemotherapy. ABCC3 was associated with lower relapse free survival (RFS) ( P = 0.02). ABCG2 was expressed at higher levels in subtypes of AML with favorable outcome but within standard‐ and high‐risk patients, it was associated with poor outcome ( P = 0.02). A strong association was observed between the number of overexpressed ABC‐transporters and the chance to achieve remission ( P = 0.01) or the chance of RFS ( P < 0.001). Conclusions: The intensive treatment regimen of AML‐BFM 2004 did not readily overcome drug resistance caused by ABC‐transporters. Inhibition of ABC‐transporters might be particularly useful in patients who express multiple of these genes.